| Income Statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Revenue | NaN | NaN | NaN | 0 |
| Research and development expenses (including non-cash stock-based compensation expenses of 286, 417, 624 and 814, respectively) | 1,258,000 | 1,102,000 | 1,505,500* | 1,055,000 |
| General and administrative expenses (including non-cash stock-based compensation expenses of 379, 571, 837 and 1,229, respectively) | 1,389,000 | 1,614,000 | 2,037,000* | 1,381,000 |
| Total operating expenses | 2,647,000 | 2,716,000 | 3,542,500 | 2,436,000 |
| Loss from operations | -2,647,000 | -2,716,000 | -3,542,500* | -2,436,000 |
| Interest income | 111,000 | 131,000 | 154,000* | 156,000 |
| Net loss | -2,536,000 | -2,585,000 | -3,388,500* | -2,280,000 |
| Less net loss attributable to noncontrolling interest | -20,000 | -20,000 | -33,500* | -22,000 |
| Net loss attributable to common shareholders | -2,516,000 | -2,565,000 | -3,355,000 | -2,258,000 |
| Basic EPS | -0.07 | -0.08 | 0.052 | -0.07 |
| Diluted EPS | -0.07 | -0.08 | 0.052 | -0.07 |
| Basic Average Shares | 33,593,000 | 33,240,000 | -64,580,638 | 32,476,000 |
| Diluted Average Shares | 33,593,000 | 33,240,000 | -64,580,638 | 32,476,000 |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)